Latest News and Press Releases
Want to stay updated on the latest news?
-
BEIJING, China, and CAMBRIDGE, Mass., Jan. 21, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
-
- SYLVANT® and QARZIBA®▼ recently listed for fast-track approval in China – - Expands EUSA’s global product offering; broadens BeiGene’s portfolio – HEMEL HEMPSTEAD, England and CAMBRIDGE, Mass. and...
-
CAMBRIDGE, Mass. and BEIJING, China, Jan. 08, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
-
Amgen Completes Purchase of Approximately $2.8 Billion of BeiGene SharesAnthony C. Hooper, Former Executive Vice President of Global Commercial Operations at Amgen, Joins BeiGene Board of Directors ...
-
Second BeiGene-discovered drug to receive regulatory approval, first in ChinaTislelizumab is an anti–PD-1 antibody specifically designed to minimize binding to FcγR on macrophages BEIJING, China and...
-
BEIJING, China and CAMBRIDGE, Mass., Dec. 22, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
-
- Primary Endpoint of Statistical Superiority Related to Deep Response (VGPR or Better) Was Not Met; However, Zanubrutinib Demonstrated More Frequent VGPRs (28.4% vs.19.2% in Overall Population)-...
-
CAMBRIDGE, Mass. and BEIJING, China, Dec. 13, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
-
Oral presentations on data from two clinical trials in chronic lymphocytic leukemia or small lymphocytic lymphoma Poster presentation on data from clinical trial of BRUKINSA combined with...
-
CAMBRIDGE, Mass. and BEIJING, China, Nov. 26, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...